neuropeptide; amphipathic; micelles; distearoyl-phosphatidylethanolamine-polyethylene glycol; vasodilation; receptor antagonist; hamster PITUITARYADENYLATECYCLASE-activatingpeptide(PACAP)-(1O38) is a 38-amino acid pleiotropic neuropeptide originally isolated from the ovine hypothalamus (2) . It is a member of the secretin/glucagon/vasoactive intestinal peptide (VIP) superfamily of peptides and shares 68% sequence homology with VIP (2, 43) . It is well established that the peptide is widely distributed in the peripheral microcirculation and on release elicits potent vasodilation (2, 13, 27, 42, 43) . However, this response is short lived, most likely because of proteolytic inactivation of the PACAP-(1O38) (13, 27, 43) . Whether the vasorelaxant effects of PACAP-(1O38) are amplified by intervention that promote peptide stability is uncertain.
To this end, previous work from our laboratory showed that VIP self-assembles in an aqueous solution to form micelles, interacts avidly with a biomimetic membrane to increase its surface pressure, and undergoes conformational transition from predominantly random coil in aqueous solutions to ␣-helix in the presence of sterically stabilized phospholipid micelles (SSM) (29, 35) . Self-association of VIP with SSM evoked significant potentiation and prolongation of the vasorelaxant effects of the peptide in the intact peripheral microcirculation relative to aqueous VIP (11, 20, 30, (35) (36) (37) (38) (39) (40) . Whether PACAP-(1O38) expresses similar properties is uncertain.
Hence, the purpose of this study was to begin to address these issues by determining whether PACAP-(1O38) self-assembles in an aqueous environment, increases surface pressure of a biomimetic phospholipid monolayer, and undergoes conformational transition in phospholipids and, if so, whether these phenomena potentiate and prolong PACAP-(1O38)-induced vasodilation in the intact peripheral microcirculation.
METHODS

Molecular Interactions of PACAP-(1O38) In Vitro
Critical micellar concentration of PACAP-(1O38). First, the surface tension of HEPES buffer (pH 7.4) contained in a 30-ml custom-made Teflon trough was determined at room temperature (25°C) by using a DuNouy surface tensiometer (model 21 Tensiomat, Fisher Scientific, Pittsburgh, PA) (10, 29) . Then, 50 l of increasing concentrations of PACAP-(1O38) (0.1-1.0 M final concentrations in the trough) dissolved in HEPES buffer (pH 7.4) were injected into the subphase through a side port and the surface tension of the PACAP-(1O38) solution was determined. The concentration above which surface tension no longer significantly decreased was considered as the critical micellar concentration (CMC) of PACAP-(1O38) (10, 29, 45) .
Effects of PACAP-(1O38) on surface pressure of a phospholipid monolayer. Dipalmitoylphosphatidylcholine (DPPC; 10 M) was dissolved in hexane-ethanol (9:1 vol/vol), and 50 l of the solution were spread over 28 ml of HEPES buffer contained in a cylindrical 30-ml custom-made Teflon trough (internal diameter, 9 cm) at room temperature (25°C). A DPPC monolayer is formed spontaneously at the buffer-air interface after total evaporation of the organic solvent in 5 min. Surface tension of the monolayer was determined every 5 min for 60 min and every 10 min for 60 min thereafter by using a DuNouy surface tensiometer. Surface pressure was defined as the difference in surface tension between the DPPC monolayer and HEPES buffer alone as previously described in our laboratory (10, 29, 45) . PACAP-(1O38) (1.5 and 3.6 M final concentration in the trough) was injected into the subphase through a side port without disturbing the DPPC monolayer. Surface tension of the DPPC monolayer containing PACAP-(1O38) was then determined as outlined above.
Conformation of PACAP-(1O38)
. PACAP-(1O38) self-associated with SSM composed of distearoyl-phosphatidylethanolamine polyethylene glycol (molecular mass of 2,000 Da) (DSPE-PEG 2000) was prepared by using a method previously described in our laboratory (10, 35) . Briefly, DSPE-PEG 2000 (1.0 mM) was dissolved in saline and mixed to form SSM. The resulting suspension was then incubated with PACAP-(1O38) for 2 h at room temperature (25°C) before use. The size of SSM alone and of PACAP-(1O38) in SSM was 18 Ϯ 1 nm as determined by quasi-elastic light scattering (QELS; model 380, Nicomp Submicron Particle Sizer, Pacific Scientific, Menlo Park, CA).
The secondary structure of PACAP-(1O38) was determined by circular dichroism. Spectra were recorded on a spectropolarimeter (model J-700, JASCO, Easton, MD) at room temperature (25°C) by using a fused quartz cell of 1-cm pathlength containing saline with PACAP-(1O38) (4 M) alone and PACAP-(1O38) (4 M) incubated with DSPE-PEG 2000 (1 mM) for 2 h. A bandwidth of 1.0 nm and a step resolution of 0.5 nm were used to collect an average of five accumulations per sample at the near-ultraviolet range (190-to 260-nm wavelength) (9, 10, 16, 24, 29, 35) . The acquired spectra were corrected to the baseline by using saline and empty SSM and were averaged. The peptide spectra were smoothed by using the noise reduction function. Data are expressed as percentage of ␣-helix by using the equation %helicity ϭ [Ϫ( ϩ 4,000)/29,000] ϫ 100 (where is ellipiticty) and were calculated by Selcon, Softsec version 1.2 (Softwood, Brookfield, CT) (10, 16, 35) . The concentrations of aqueous PACAP-(1O38) and PACAP-(1O38) in SSM used in these experiments are based on previous studies with VIP and secretin in our laboratory (6, 10, 11, 20, 29, 30, (35) (36) (37) (38) (39) (40) .
Effects of PACAP-(1O38) on Arteriolar Diameter In Vivo
Preparation of animals. Adult golden Syrian hamsters (120-140 g body wt) were anesthetized with pentobarbital sodium (6 mg/100 g body wt ip). A tracheostomy was performed to facilitate spontaneous breathing. The left femoral vein was cannulated to inject supplemental anesthesia (2-4 mg ⅐ 100 g body wt Ϫ1 ⅐ h Ϫ1 ) during the experiment. A catheter was inserted into the left femoral artery and connected to a computer-monitored pressure transducer to record systemic arterial pressure and heart rate (Workbench for Windowsϩ, Kent Scientific, Torrington, CT), which did not change significantly during the experiment. Body temperature was monitored and maintained constant (37-38°C) throughout the experiment by using a heating pad.
To visualize the microcirculation of the cheek pouch, we used an established method in our laboratory and the literature (7, 10-12, 20, 30, 31, 34-40) . Briefly, the left cheek pouch was spread over the small plastic baseplate, and an incision was made in the outer skin to expose the cheek pouch membrane. The avascular connective tissue layer of the membrane was removed, and a plastic chamber was positioned over the baseplate and secured in place by suturing the skin around the upper chamber. This chamber was connected to a reservoir containing warmed bicarbonate buffer (37-38°C), which allowed continuous suffusion onto the cheek pouch. The bicarbonate buffer was bubbled continuously with 95% N 2-5% CO2 (pH 7.4). The chamber was also connected via a three-way valve to an infusion pump (Sage Instruments, Boston, MA) that allowed constant administration of drugs into the suffusate.
Determination of arteriolar diameter. The cheek pouch microcirculation was visualized with a microscope (Nikon, Tokyo, Japan) coupled to a 100-W mercury light source at a final magnification of ϫ40. The microscope image was projected through a low-light television camera (Panasonic TR-124 MA, Matsushita Communication Industrial, Yokohama, Japan) onto a video screen (Panasonic). The inner diameter of second-order arterioles (baseline diameter, 48-60 m), which modulate microvascular resistance in the cheek pouch (7, 31) , was determined during the experiment from the video display of the microscope image by using a videomicrometer (model VIA 100, Boeckler Instruments, Tuscon, AZ; resolution, Ϯ1 m). In each animal, the same arteriolar segment was used to measure vessel diameter during the experiment.
Experimental Design PACAP-(1O38)-induced vasodilation.
The purpose of these studies was to determine whether self-association of PACAP-(1O38) with SSM potentiates and prolongs the vasorelaxant effects of the peptide in the intact cheek pouch microcirculation. Animals were divided into six groups, with four animals in each group. After suffusion of the bicarbonate buffer for 30 min (equilibration period), the cheek pouch was suffused with increasing concentrations of PACAP-(1O38) (0.01, 0.1, and 1.0 nmol) in saline or in SSM. Each concentration was suffused for 7 min in an arbitrary fashion. At least 45 min elapsed between subsequent suffusions of PACAP-(1O38) (30, 35, 37) . Arteriolar diameter was determined every 5 min during the equilibration period, immediately before, every minute during, and after suffusion of PACAP-(1O38) until arteriolar diameter returned to baseline. In preliminary studies, we determined that repeated suffusions of PACAP-(1O38) (0.01, 0.1, and 1.0 nmol) in saline and in SSM were associated with reproducible results (each group, n ϭ 4 animals; P Ͼ 0.5; data not shown). In addition, suffusions of saline [vehicle of PACAP-(1O38) and PACAP-(1O38) in SSM] and of empty SSM for the duration of the experiments were associated with no significant changes in arteriolar diameter (each group, n ϭ 4 animals; P Ͼ 0.5; data not shown). The concentrations of PACAP-(1O38) in saline and in SSM used in these experiments were based on preliminary studies.
Effects of receptor antagonists on PACAP-(1O38)-induced vasodilation.
The purpose of these studies was to determine whether the vasorelaxant effects of PACAP-(1O38) in the intact cheek pouch are mediated by activation of specific receptors. Four groups (each, n ϭ 4 animals) were studied. After the equilibration period, the cheek pouch was suffused for 7 min with PACAP-(1O38) in saline (1.0 nmol) or PACAP-(1O38) in SSM (0.1 nmol). These concentrations were chosen because they elicited vasodilation of similar magnitude in the experiments outlined above. Thereafter, bicarbonate buffer was suffused for 30 min followed by 30-min suffusion of PACAP-(6O38) (10 nmol), a PACAP-(1O38) receptor antagonist (8, 17, 18, 22, 25, 26, 32, 41) , or VIP-(10O28) (10 nmol), a VIP-receptor antagonist (1, 5, 8, 16, 23, 37) , followed by 7-min suffusion of PACAP-(1O38) in saline (1.0 nmol) or PACAP-(1O38) in SSM (0.1 nmol). Arteriolar diameter was determined after each intervention as outlined above. In preliminary experiments, we determined that 30-min suffusion of PACAP-(6O38) and VIP-(10O28) (each, 10 nmol) alone had no significant effects on arteriolar diameter (each group, n ϭ 4 animals; P Ͼ 0.5; data not shown). The concentrations of PACAP-(6O38) and VIP-(10O28) used in these experiments are based on preliminary studies and previous reports from our laboratory and in the literature (21, 27, 37) .
Chemicals and Drugs
Human PACAP-(1O38) was synthesized by Dr. Robert Lee at the Protein Research Laboratory, University of Illinois at Chicago (Chicago, IL). VIP-(10O28) and PACAP-(6O38) were obtained from American Peptide (Sunnyvale, CA). Bicarbonate buffer (in mM: 131.9 NaCl, 0.76 MgCl 2, 2.95 KCl, 11.87 NaHCO3, and 1.48 CaCl2) and HEPES were obtained from Sigma Chemical (St. Louis, MO). DSPE-PEG 2000 and DPPC were obtained from Avanti Polar Lipids (Alabaster, AL). All drugs were prepared and diluted in saline to the desired concentrations on the day of the experiment.
Data and Statistical Analyses
When a compound was suffused onto the cheek pouch, we determined the maximal change in arteriolar diameter and considered it the response to that compound in each animal. Arteriolar diameter was expressed as the ratio of experimental diameter to control diameter, with control diameter normalized to 100%, to account for intra-animal and interanimal variability. Data are expressed as means Ϯ SE except for the size of micelles, which is expressed as means Ϯ SD because these data were not used to compare between experimental groups. Statistical analysis was performed by using repeatedmeasures analysis of variance with Neuman-Keuls multiplerange post hoc test to detect values that were different from control values. A value of P Ͻ 0.05 was considered statistically significant.
RESULTS
Molecular interactions of PACAP-(1O38) In Vitro
CMC of PACAP-(1O38).
The effects of injection of PACAP-(1O38) into the subphase of HEPES buffer (pH 7.4) on surface tension are shown in Fig. 1 . The peptide elicited a significant concentration-dependent decrease in surface tension from baseline ( Fig. 1 ; n ϭ 3 experiments; P Ͻ 0.05). No significant change was observed above PACAP-(1O38) concentration of 0.4-0.9 M, so this range was taken as the CMC of PACAP-(1O38) (Fig. 1) . The size of PACAP-(1O38) micelles was below the lower detection limit of the QELS apparatus (5 nm).
Effects of PACAP-(1O38) on membrane surface pressure of a phospholipid monolayer. The effects of PACAP-(1O38) on surface pressure of a DPPC monolayer is depicted in Fig. 2 . The DPPC monolayer alone is unstable at the air-water interface and decomposes shortly after spreading, leading to a sustained decline in surface pressure relative to baseline ( Fig. 2 ; n ϭ 3 animals; P Ͻ 0.05). By contrast, injection of PACAP-(1O38) (1.5 and 3.6 M) into the subphase stabilized the DPPC monolayer as manifested by a dose-dependant increase in surface pressure of the monolayer over a sustained period of time ( Fig. 2 ; each group, n ϭ 3 experiments; P Ͻ 0.05). The increase in the surface pressure during the first 20 min of the experiment indicates incorporation of PACAP-(1O38) into the monolayer ( Fig. 2 ; each group, n ϭ 3 experiments; P Ͻ 0.05).
Conformation of PACAP-(1O38).
The conformation of PACAP-(1O38) in saline at room temperature was unordered (␣-helix content, 3.0 Ϯ 1.0%; n ϭ 3 experiments). By contrast, association of PACAP-(1O38) with DSPE-PEG 2000 at room temperature was associated with a significant increase in the proportion of ␣-helix [␣-helix content, 13.0 Ϯ 4.1%; n ϭ 3 experiments; P Ͻ 0.05 compared with PACAP-(1O38) in saline].
Effects of PACAP-(1O38) on Arteriolar Diameter in Vivo PACAP-(1O38)-induced vasodilation.
Suffusion of PACAP-(1O38) elicited a significant, concentrationdependent increase in arteriolar diameter ( Fig. 3 ; each group, n ϭ 4 animals; P Ͻ 0.05 compared with baseline). Vasodilation was observed within 1-2 min after the start of suffusion, was maximal within 5-6 min, and returned to baseline within 25 min thereafter. Self-association of PACAP-(1O38) with SSM significantly potentiated the vasorelaxant effects of the peptide ( Fig. 3 ; each group, n ϭ 4 animals; P Ͻ 0.05 compared with PACAP in saline). In addition, the duration of vasodilation evoked by PACAP-(1O38) in SSM was significantly longer than that elicited by PACAP-(1-38) in saline (Fig. 4 , each group, n ϭ 4 animals; P Ͻ 0.05). these experiments because they display agonist-like activity in the cheek pouch (37) .
Effects of receptor antagonists on PACAP-(1O38)-induced vasodilation. Suffusion of PACAP-(6O38)
(
DISCUSSION
There are three new findings of this study. First, we found that PACAP-(1O38), a pleiotropic neuropeptide with a calculated net charge of ϩ7 (2, 43), self-assembles in an aqueous solution in vitro with a CMC of 0.4-0.9 M. Second, PACAP-(1O38) , at concentrations detected in the synaptic cleft (2, 8, 43) , increases significantly the surface pressure of a biomimetic monolayer over a sustained period of time. Taken together, these data indicate that PACAP-(1O38) at physiological concentrations is an amphipathic neuropeptide because it self-aggregates in an aqueous environment and interacts avidly with phospholipids.
This conclusion is supported by the observed change in molecular conformation of PACAP-(1O38) in the presence of DSPE-PEG 2000. There was a significant transition of the secondary structure of PACAP-(1O38) from predominantly random coil in saline to ␣-helix in the presence of phospholipids. ␣-Helix is the optimal conformation for PACAP-(1O38) to interact with its receptors in target cells and also confers stability to the peptide (3, 9, 10, 14, 16, 24, 28, 29, 33, 35, 44) . To this end, Gao et al. (11) showed that association of VIP with liposomes protects the peptide from degradation by trypsin in vitro. Whether self-association of PACAP-(1O38) with SSM also protects the peptide from proteolysis remains to be determined.
The third new finding of this study is that suffusion of aqueous (random coil) PACAP-(1O38) onto the intact hamster cheek pouch microcirculation elicited significant concentration-dependent vasodilation that was attenuated by PACAP-(6O38), a PACAP type 1 (PAC 1 ) and PACAP/VIP type 2 (VPAC 2 ) receptor antagonist, but not by VIP-(10O28), a PACAP/VIP type 1 (VPAC 1 )/VPAC 2 receptor antagonist (1, 5, 17, 18, 22, 23, 26, 32, (41) (42) (43) . Self-association of PACAP-(1O38) with SSM [␣-helix PACAP-(1O38)] significantly potentiated and prolonged vasodilation evoked by the peptide relative to that elicited by aqueous PACAP-(1O38). However, unlike aqueous PACAP-(1O38), the vasorelaxant effects of PACAP-(1O38) in SSM were attenuated by both VIP-(10O28) and PACAP-(6O38). The magnitude of micellar PACAP-(1O38)-induced vasodilation and its duration were similar to those evoked by micellar VIP in the cheek pouch (30, 35) . Collectively, these data suggest that the spontaneous interactions of amphipathic neuropeptides with SSM in vitro are driven by common biophysical properties.
The mechanisms underlying PACAP-(1O38) interactions with phospholipids were not elucidated in this study. Nonetheless, the results of this study suggest that PACAP-(1O38) is attracted to and inserts itself into a phospholipid monolayer and SSM. This process is governed, most likely, by electrostatic and hydrophobic forces, leading to an increase in the membrane surface pressure (10, 29, 45) . Although the physiological significance of these phenomena are uncertain, they nonetheless suggest that PACAP-(1O38) interacts directly with phospholipids in the plasma and organelle membranes in target cells, thereby altering membrane fluidity and intracellular signal transduction pathway(s) (10, 14, (28) (29) (30) . Whether amphipathic neuropeptides, such as PACAP-(1O38), VIP, and secretin, associate spontaneously with phospholipids, such as lipoproteins, to form micelles in biological fluids remains to be established.
The hamster cheek pouch is an established animal model to elucidate the mechanisms underlying the vasoactive effects of various endogenous mediators, including VIP and PACAP-(1O38), in the intact peripheral microcirculation (7, 11, 12, 30, 31, (34) (35) (36) (37) (38) (39) (40) . This intravital preparation is stable for at least 6 h, thereby allowing each animal to be used as its own control. This, in turn, reduces the number of animals required for each experiment and simplifies data analysis (11, 12, 30, (34) (35) (36) (37) (38) (39) (40) .
The results of this study indicate that phospholipidinduced transition of PACAP-(1O38) secondary structure from random coil to ␣-helix not only amplifies vasodilation evoked by the peptide in the intact peripheral microcirculation but also shifts the receptor subtype activated by PACAP-(1O38) from predominantly PAC 1 receptors for aqueous (random coil) PACAP-(1O38) to predominantly VPAC 1 /VPAC 2 receptors for phospholipid-associated (␣-helix) PACAP-(1O38). These data suggest a promiscuous behavior of PACAP-(1O38) in target cells, which is dependent, in part, on the biophysical state of the peptide and phospholipids in the interstitial fluid-plasma membrane interface (15, 32, 43) . Clearly, the molecular mechanisms and intracellular signal transduction pathway(s) underlying this proposed phospholipid-dependent receptor shift in the intact peripheral microcirculation and its relevance to other biological effects of PACAP-(1O38) in vivo should be further probed by using more selective PACAP-(1O38) agonists and PAC 1 , VPAC 1 , and VPAC 2 receptor antagonists as they become commercially available (43) .
In summary, we found that PACAP-(1O38) is an amphipathic neuropeptide that self-assembles in an aqueous solution and interacts avidly with a biomimetic monolayer, leading to a significant and sustained increase in the surface pressure of the monolayer. In addition, PACAP-(1O38) undergoes conformational transition from predominantly random coil in saline to ␣-helix in the presence of SSM. Importantly, self-association of PACAP-(1O38) with sterically stabilized phospholipid micelles potentiates and prolongs the vasorelaxant effects of the peptide in the intact peripheral microcirculation while shifting its receptor subtype specificity from predominantly PAC 1 receptors to predominantly VPAC 1 /VPAC 2 receptors. We suggest that PACAP-(1O38) interactions with phospholipids modulate, in part, its vasoactive effects in vivo.
